Therapeutic uncertainties in people with cardiometabolic diseases and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19).

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19) was declared a pandemic by the World Health Organisation (WHO) and sent each country scrambling to review emergency healthcare provisions. There is global evidence of each nation struggling to effectively manage the number of people being diagnosed with the virus. These are testing times which have not been experienced in recent generations and there are a number of insecurities regarding the management of people with COVID-19 and cardiometabolic diseases. This review highlights the current concerns related to COVID-19 and provides advice in terms of the therapeutic uncertainty and potential adverse harms with therapy when managing people particularly those with cardiometabolic diseases who have contracted or are at increased risk of contracting COVID-19. This article is protected by copyright. All rights reserved.